Liquid Biopsy and Primary Brain Tumors

Two decades of "promising results" in liquid biopsy have led to both continuing disappointment and hope that the new era of minimally invasive, personalized analysis can be applied for better diagnosis, prognosis, monitoring, and therapy of cancer. Here, we briefly highlight the promises,...

Full description

Saved in:
Bibliographic Details
Published inCancers Vol. 13; no. 21; p. 5429
Main Authors Eibl, Robert H, Schneemann, Markus
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 29.10.2021
MDPI
Subjects
Biomarkers
Biopsy
Blood-brain barrier
Body fluids
Brain cancer
Brain tumors
Cerebrospinal fluid
DNA methylation
DNA repair
Glioblastoma
Histology
Medical prognosis
Microscopy
miRNA
Mutation
Patients
Proteins
Review
Stem cells
Tumor cells
Tumors
Vesicles
circulating tumor (ct)DNA
glioblastoma
circulating tumor cell—CTC
medulloblastoma
microRNA—miR
brain tumor
glioma
biomarker
extracellular vesicle
liquid biopsy
Online AccessGet full text

Cover

More Information
Summary:Two decades of "promising results" in liquid biopsy have led to both continuing disappointment and hope that the new era of minimally invasive, personalized analysis can be applied for better diagnosis, prognosis, monitoring, and therapy of cancer. Here, we briefly highlight the promises, developments, and challenges related to liquid biopsy of brain tumors, including circulating tumor cells, cell-free nucleic acids, extracellular vesicles, and miRNA; we further discuss the urgent need to establish suitable biomarkers and the right standards to improve modern clinical management of brain tumor patients with the use of liquid biopsy.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers13215429